NCT06901609View on ClinicalTrials.gov

Effect of Genetic Polymorphism on the Clinical Outcome to SGLT2 Inhibitors in Heart Failure Patients

Active, not recruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

November 22, 2023

Primary Completion Date

June 1, 2025

Study Completion Date

July 1, 2025

Conditions
Heart Failure - NYHA II - IVCardiac FibrosisCardiac Remodeling
Interventions
DRUG

SGLT2 inhibitor (Dapagliflozin 10mg)

Renal response after 6 months of Dapagliflozin therapy among patients with heart failure reduced ejection fraction.

Trial Locations (1)

11315

National Heart Institute, Cairo

All Listed Sponsors
collaborator

National Heart Institute in Egypt

UNKNOWN

collaborator

Misr International University

OTHER

collaborator

Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia

UNKNOWN

lead

Ain Shams University

OTHER